"This was the largest nationwide population-based longitudinal cohort study to investigate the association between the use of ...

The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to ...

A meta-analysis has demonstrated consistent efficacy in heart failure outcomes with SGLT2 inhibitors regardless of disease ...

New data suggest that current recommendations overstate the proportion of patients who would receive significant kidney ...

Recent study highlights a significant care gap due to the underuse of SGLT2 inhibitors, despite their benefits. Canada: A ...

The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to ...

A total of 77 suicide deaths in GLP-1 agonist users and 71 in SGLT2 inhibitor users were identified. Subgroup analyses ...

New findings add to the pile of research on the possible neuroprotective effects of drugs like dapagliflozin, empagliflozin, and dulaglutide for patients with type 2 diabetes. New research ...

When it comes to kidney and cardiovascular outcomes, there is no significant difference between treatment with an SGLT2 inhibitor or GLP-1 receptor agonist in patients with type 2 diabetes, according ...

Empagliflozin, an SGLT2 inhibitor, is proven safe and effective for heart attack patients, offering a new treatment option to ...

Estimated risk difference varied from −2.45 to 0.63 percentage points with SGLT2 vs dulaglutide among older adults. HealthDay News — For older adults with type 2 diabetes, the risk for ...